BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Sistemic & Cynata sign Global Service & License Agreement for the use of SistemPSCCheck™
Sistemic Cynata

Sistemic & Cynata sign Global Service & License Agreement for the use of SistemPSCCheck™

October 22, 2018 By Cade Hildreth (CEO) Leave a Comment

Glasgow, United Kingdom; 22nd October 2018: Sistemic Ltd. is pleased to announce the completion of a Global Service and License Agreement for its SistemPSCCheck™ assay with Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd. The agreement will see the use of the SistemPSCCheck™ assay for the assessment of residual pluripotent stem cells in Cynata’s current iPSC-derived MSC clinical candidate CYP-001, as well other planned iPSC-derived MSC products.

Discover class-defining bioproduction tools.

SistemPSCCheck™ is a first-in-class miRNA-based assay for high sensitivity assessment of residual pluripotent stem cells (PSCs) in derived cell preparations. It has been specifically designed to offer high levels of safety for characterisation and batch release testing to support the clinical and commercial development of PSC cell-derived cell therapy products.

Jim Reid, CEO stated, “We have been working with Cynata for a number of years now but this agreement is a significant milestone for Sistemic. Working with the company who is leading the field in iPSC-derived cell therapies is a fantastic position for Sistemic to be in. On the back of Cynata’s recently announced positive clinical data, this is another step on the way to the introduction of commercially viable, efficacious and safe cell therapy products”.

David Mallinson, VP of Scientific Operations added, “Over the past two years we have developed and validated the SistemPSCCheck™ assay to produce an off-the-shelf assay product for residual PSC assessment with class-defining detection sensitivity and diagnostic accuracy. We we are delighted to be working with Cynata using SistemPSCCheck™ and are looking forward to supporting the further clinical development of CYP-001, as well as their other planned iPSC-derived MSC products”.

Rooster DevServices

Sistemic

Sistemic’s primary business is focused on providing innovative micro-RNA-based problem-solving services and products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell and Gene Therapy research, development and manufacturing markets.

For more information contact: [email protected]

bitbio
5/5 - (3 votes)

Filed Under: iPS Cells, Stem Cell News Tagged With: cynata therapeutics, Sistemic Ltd

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.